<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993093</url>
  </required_header>
  <id_info>
    <org_study_id>SinghRK1</org_study_id>
    <nct_id>NCT03993093</nct_id>
  </id_info>
  <brief_title>Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre</brief_title>
  <acronym>ADC</acronym>
  <official_title>AIDS Defining Opportunistic Infections in Naive HIV Cases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singh, Ranjan Kumar, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singh, Ranjan Kumar, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV patients are likely to suffer from opportunistic infections, in absence of highly active
      retroviral therapy. This happens due to lack of awareness of HIV status among patients or
      unresponsive to anti retroviral drugs. This study is for the prevalence of AIDS defining OIs
      among treatment naive HIV patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oppotunistic infections (OIs) happen in persons with weakened immune system. HIV patients,
      who remain untreated due to lack of knowledge of existing HIV infections, often get OIs. HIV
      patients with AIDS defining OIs fall into stage 3 of HIV illness. Prevalence of OIs in
      resource poor settings are tuberculosis (pulmonary and extra pulmonary), toxoplasmosis,
      cryptococcosis, and oesophageal candidiasis. There are a few data to show AIDS defining OIs
      in treatment naïve HIV patients. Incidence of OIs among HIV patients in United States, and
      Canada between 2000 to 2019 was 9%. Leading OIs were peumocystis Jiroveci, oesophageal
      candidiasis and disseminated MAC or M. kansassi.

      Minimal diagnoses at poor settings can be made by observation of symptoms, use of microscope,
      imaging and diagnostic therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">March 15, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of AIDS defining OIs</measure>
    <time_frame>Six months</time_frame>
    <description>Calculate number of total HIV patients with or without opportunistic infections (n). Again calculate no of HIV patients with opportunistic infections (n1). Then calculate prevalence of HIV +ve patients with opportunistic infections by applying formula n1/n x100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare CD4 cell in cases of HIV with OIs with CD4 cell of HIV patients without OIs</measure>
    <time_frame>Six months</time_frame>
    <description>Find out CD4 cell counts (cells /μL) of HIV patients with CD4 cell counts (cells/μL) of HIV patients without OIs. By calculating mean/SD of CD4 cells in both groups, comparison by chi square test would be done.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">257</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <condition>Candidiasis, Esophageal</condition>
  <condition>Cryptococcosis</condition>
  <condition>Leishmaniasis</condition>
  <condition>Toxoplasmosis</condition>
  <arm_group>
    <arm_group_label>HIV with OIs</arm_group_label>
    <description>Treatment naive HIV patients with OIs</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CD4 cell count</intervention_name>
    <description>CD4 cell count from treatment naive HIV patients</description>
    <arm_group_label>HIV with OIs</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Antiretroviral treatment naive HIV patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • HAART naïve HIV patient

        Exclusion Criteria:

          -  Patients died during screening

          -  Transferred in HIV patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranjan K Singh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singh, Ranjan Kumar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ART centre, Sadar Hospital</name>
      <address>
        <city>Khagaria</city>
        <state>Bihar</state>
        <zip>851204</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Singh, Ranjan Kumar, M.D.</investigator_affiliation>
    <investigator_full_name>Ranjan Kumar Singh</investigator_full_name>
    <investigator_title>Physician, cum nodal officer, ART centre Khagaria</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Opportunistic infection</keyword>
  <keyword>CD4+ T cells</keyword>
  <keyword>AIDS defining condition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Opportunistic Infections</mesh_term>
    <mesh_term>Cryptococcosis</mesh_term>
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Toxoplasmosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

